Skip to main content

Klein Lawrence Otto's Form 4 filing

Oruka Therapeutics, Inc. (ORKA) · filed Sep 1, 2026

Accession no.
0000907654-26-000087
Filed
Sep 1, 2026, 6:35 PM ET
Trade date
Sep 1, 2026
Filing delay
Same day
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $6.89M. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Klein Lawrence OttoCIK 0001762583Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 1, 2026Common StockMOption exerciseAcquired+75,000$7.80+$585,0001,000,580Direct
Sep 1, 2026Common StockSSaleDisposed−6,604$90.79−$599,556.03993,976Direct
Sep 1, 2026Common StockSSaleDisposed−63,596$91.90−$5,844,237.09930,380Direct
Sep 1, 2026Common StockSSaleDisposed−4,800$92.44−$443,691.36925,580Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 1, 2026Common StockMOption exerciseDisposed−75,000$0.00$01,553,513Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)